Home โ€บ Mental Health โ€บ Clinical Trial
Clinical Trial ยท PHASE2 ยท Recruiting

A Phase 2a Efficacy, Safety, Tolerability, and PK Study of SYT-510 in Participants With Generalized Anxiety Disorder

07 September 2026 NCT07478744 ClinicalTrials.gov โ†—
✅ This trial is currently recruiting volunteers
If you think you might be eligible, speak to your GP or specialist about this trial before applying.
Status
Recruiting
Phase
PHASE2
Participants
ALL
Age Range
18 Years โ€“ 55 Years

About This Trial

This is a single dose study to investigate the efficacy, safety, tolerability and the PK, of SYT-510 in participants who meet diagnostic criteria of GAD. This study represents an evaluation of the effects of SYT-510 in participants meeting DSM-5 GAD diagnostic criteria. As a single dose study, it is designed to evaluate the efficacy of SYT-510 on neurobiological and behavioral markers associated with anxiety and will inform the design of future clinical trials in anxiety disorders. By integrating efficacy / PD, safety, tolerability, and PK measures within the same study framework, the study enables the translational value of the program, ensuring a more comprehensive understanding of SYT-510 effects in patients with generalized anxiety disorders. The plan is to evaluate a single dose of SYT-510 as compared with its matching placebo in a two-way crossover design, separated by a washout period of 7 to 14 days.

Who Can Join?

Inclusion Criteria: 1. Males or females aged 18 to 55 years old (inclusive) at the date of signing the ICF. 2. Participants who are currently unmedicated and meet the criteria for GAD as defined in the DSM-5 by using the MINI. 3. Participants must be right-handed. 4. BMI between 18 and 30 kg/m2, inclusive, at Screening and a minimum weight of 50 kg. 5. Contraception use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. 6. Participants must agree not to donate sperm or ova from the time of the first administration of study drug (T1, D2) until 3 months after the participant's last visit. 7. Ability to provide written, personally signed, and dated informed consent to participate in the study, in accordance with the current version of the ICH GCP Guideline E6 and applicable regulations, before completing…

⚠ Always speak to your doctor before applying to any clinical trial.

Clinical trials can speed up access to new treatments

Joining a trial may give you access to cutting-edge therapies before they're widely available on the NHS — while helping advance medical research.

More Mental Health Trials

Free health updates

Stay one step ahead
of your condition.

New trial alerts, treatment news, and plain-English updates โ€” matched to your condition. Free forever.

No spam. Unsubscribe anytime. Your data is private.